Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study

被引：0
|
作者：
Zhang, G. [1 ]
He, Y. [1 ]
Luo, D. [1 ]
Zhang, X. [1 ]
Gao, B. [1 ]
Jiang, Y. [1 ]
Zhao, J. [1 ]
Guo, L. [1 ]
Xu, Y. [1 ]
机构：
[1] Army Specialty Med Ctr PLA, Dept Breast & Thyroid Surg, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26TiP
引用
收藏
页码：S1414 / S1414
页数：1
相关论文
共 50 条
  • [31] Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer
    Somlo, G.
    Chung, S.
    Frankel, P.
    Hurria, A.
    Koehler, S.
    Kruper, L.
    Mortimer, J. E.
    Paz, B.
    Robinson, K.
    Taylor, L.
    Vito, C.
    Waisman, J.
    Yeon, C.
    Yim, J.
    Yuan, Y.
    Tong, T.
    CANCER RESEARCH, 2016, 76
  • [32] Anthracycline-free neoadjuvant therapy with nab-paclitaxel and carboplatin in nonluminal breast cancer: a single-arm phase II trial
    Liu, Deyue
    Zhu, Li
    Wu, Jiayi
    Wang, Wei
    Ding, Shuning
    CANCER RESEARCH, 2024, 84 (09)
  • [33] A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
    Yam, Clinton
    Mittendorf, Elizabeth A.
    Garber, Haven R.
    Sun, Ryan
    Damodaran, Senthil
    Murthy, Rashmi K.
    Ramirez, David
    Karuturi, Meghan
    Layman, Rachel M.
    Ibrahim, Nuhad
    Rauch, Gaiane M.
    Adrada, Beatriz E.
    Candelaria, Rosalind P.
    White, Jason B.
    Ravenberg, Elizabeth
    Clayborn, Alyson
    Ding, Qing Qing
    Symmans, W. Fraser
    Prabhakaran, Sabitha
    Thompson, Alastair M.
    Valero, Vicente
    Tripathy, Debu
    Huo, Lei
    Moulder, Stacy L.
    Litton, Jennifer K.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (03) : 457 - 469
  • [34] A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
    Clinton Yam
    Elizabeth A. Mittendorf
    Haven R. Garber
    Ryan Sun
    Senthil Damodaran
    Rashmi K. Murthy
    David Ramirez
    Meghan Karuturi
    Rachel M. Layman
    Nuhad Ibrahim
    Gaiane M. Rauch
    Beatriz E. Adrada
    Rosalind P. Candelaria
    Jason B. White
    Elizabeth Ravenberg
    Alyson Clayborn
    Qing Qing Ding
    W. Fraser Symmans
    Sabitha Prabhakaran
    Alastair M. Thompson
    Vicente Valero
    Debu Tripathy
    Lei Huo
    Stacy L. Moulder
    Jennifer K. Litton
    Breast Cancer Research and Treatment, 2023, 199 : 457 - 469
  • [35] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Eguchi, Susumu
    Inomata, Masafumi
    Nishihara, Kazuyoshi
    Shinchi, Hiroyuki
    Okuda, Koji
    Baba, Hideo
    Nagano, Hiroaki
    Ueki, Toshiharu
    Noshiro, Hirokazu
    Nakamura, Masafumi
    INTERNATIONAL JOURNAL OF SURGERY PROTOCOLS, 2021, 25 (01): : 55 - 60
  • [36] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Saha, Poornima
    Rampurwala, Murtuza M.
    Kamaraju, Sailaja
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Matossian, Margarite
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
  • [38] Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial
    Chen, Li
    Jiang, Yi-Zhou
    Wu, Songyang
    Wu, Jiong
    Di, Genhong
    Liu, Guangyu
    Yu, Keda
    Fan, Lei
    Li, Junjie
    Hou, Yifeng
    Hu, Zhen
    Chen, Canming
    Huang, Xiaoyan
    Cao, Ayong
    Hu, Xin
    Zhao, Shen
    Ma, Xiaoyan
    Zhu, Xiaoyu
    Zou, Jianjun
    Yang, Wentao
    Wang, Zhonghua
    Shao, Zhi-ming
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer
    Fan, Lei
    Liu, Xiyu
    Xu, Ying
    Sui, Xinyi
    Zhang, Wenjuan
    Ma, Linxiaoxi
    Jin, Xi
    Wu, Song-Yang
    Wang, Han
    Xiao, Yi
    Chen, Li
    Wu, Jiong
    Yu, Ke-da
    Liu, Guangyu
    Hu, Xin
    Wang, Zhonghua
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer- A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
    Fasching, Peter A.
    Hein, Alexander
    Kolberg, Hans-Christian
    Haeberle, Lothar
    Uhrig, Sabrina
    Ruebner, Matthias
    Belleville, Erik
    Hack, Carolin C.
    Fehm, Tanja N.
    Janni, Wolfang
    Hartmann, Arndt
    Erber, Ramona
    Theuser, Anna-Katharin
    Brucker, Sara Y.
    Hartkopf, Andreas D.
    Untch, Michael
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 1 - 9
12345